Van ECK Associates Corp Decreases Stock Holdings in Haleon plc (NYSE:HLN)

Van ECK Associates Corp decreased its stake in Haleon plc (NYSE:HLN) by 5.5% in the third quarter, Holdings Channel.com reports. The firm owned 3,090,791 shares of the company’s stock after selling 181,404 shares during the period. Van ECK Associates Corp’s holdings in Haleon were worth $30,599,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new position in Haleon in the third quarter worth about $28,000. Cultivar Capital Inc. purchased a new position in shares of Haleon during the 2nd quarter worth approximately $40,000. Allspring Global Investments Holdings LLC acquired a new stake in Haleon in the 1st quarter valued at about $43,000. Hexagon Capital Partners LLC increased its stake in Haleon by 66.6% in the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after purchasing an additional 2,677 shares during the last quarter. Finally, BOKF NA raised its stake in Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after acquiring an additional 2,842 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Performance

Haleon stock opened at $9.76 on Tuesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock has a market cap of $44.18 billion, a P/E ratio of 28.71, a price-to-earnings-growth ratio of 2.83 and a beta of 0.30. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80. The stock has a 50 day moving average of $10.23 and a 200-day moving average of $9.27.

Wall Street Analysts Forecast Growth

HLN has been the topic of several research analyst reports. Berenberg Bank began coverage on Haleon in a research report on Tuesday, August 6th. They set a “buy” rating on the stock. UBS Group raised Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Morgan Stanley increased their price target on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. Finally, The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Haleon presently has an average rating of “Buy” and an average target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.